Siginificance of Neoadjuvant Chemotherapy on Expression of P53/bcl- 2 in Breast Cancer

DAI Zhi-jun,WANG Xi-jing,MA Hui,LIU Xiao-xu,XUE Feng-jie,XUE Xing-huan,KANG Hua-feng
DOI: https://doi.org/10.3969/j.issn.1672-4992.2006.01.019
2006-01-01
Journal of Modern Oncology
Abstract:Objective To study the significance of neoadjuvant chemotherapy on p53/bcl -2 expression in breast cancer. Methods The study group which was treated with neoadjuvant chemotherapy (n = 97) and the control groupwhich did not accept neoadjuvant chemotherapy (n --79) were analyzed for expression of p53/bcl -2, and the DSF was also analyzed. Results p53 protein was expressed in 28 of 97 cases(28.9% ) in study group , while 29 of 76cases (38.2%) in control group;bcl-2 protein was expressed in 39 of 97 cases(40.2% ) in study group ,while 43of 76 cases(56.7% ) in control group;5 year - DFS in study group was 74.2% (72/79) ,while 60.5% (46/76) in control group. All the result was statistically significant. Conclusion It is possible that neoadjuvant chemotherapy can improve prognosis through adjusting expression of p53/bcl - 2.
What problem does this paper attempt to address?